Vanheilen Pharmaceuticals India Profile
Key Indicators
- Authorised Capital ₹ 0.40 M
- Paid Up Capital ₹ 0.40 M
- Company Age 9 Year, 2 Months
- Last Filing with ROC 31 Mar 2018
- Revenue Growth %
- Profit Growth 18.27%
- Ebitda 18.27%
- Net Worth -62.97%
- Total Assets 24.33%
About Vanheilen Pharmaceuticals India
Vanheilen Pharmaceuticals India Private Limited (VPIPL) is a Private Limited Indian Non-Government Company incorporated in India on 12 November 2015 (Nine years and two months 29 days old ). Its registered office is in Kollam, Kerala, India.
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2018. It's a company limited by shares with an authorized capital of Rs 0.40 M and a paid-up capital of Rs 0.40 M, as per Ministry of Corporate Affairs (MCA) records.
Akhil Dinamani, Vince, Sameer Sainudeen, and One other member serve as directors at the Company.
Company Details
-
Location
Kollam, Kerala, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24231KL2015PTC039482
-
Company No.
039482
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
12 Nov 2015
-
Date of AGM
29 Sep 2018
-
Date of Balance Sheet
31 Mar 2018
-
Listing Status
Unlisted
-
ROC Code
Roc Ernakulam
Industry
Who are the key members and board of directors at Vanheilen Pharmaceuticals India?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Akhil Dinamani
|
Managing Director | 12-Nov-2015 | Current |
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Vince
|
Director | 12-Nov-2015 | Current |
|
Sameer Sainudeen
|
Director | 24-Nov-2015 | Current |
|
Jayasree Pillai
|
Director | 24-Nov-2015 | Current |
Financial Performance of Vanheilen Pharmaceuticals India.
Vanheilen Pharmaceuticals India Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 18.27% increase in profit. The company's net worth observed a substantial decline by a decrease of 62.97%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Vanheilen Pharmaceuticals India?
In 2017, Vanheilen Pharmaceuticals India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Vanheilen Pharmaceuticals India?
Unlock and access historical data on people associated with Vanheilen Pharmaceuticals India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Vanheilen Pharmaceuticals India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Vanheilen Pharmaceuticals India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.